May 24, 2022 / 01:15PM GMT
Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
Hi. Good morning, everyone. I'm Ellie Merle. I'm one of the biotech analysts here at UBS. Thank you so much for joining us at the UBS Healthcare Conference in person.
Very happy to have Moderna here with us for a fireside chat. Joining us from Moderna is Lavina Talukdar, SVP, Head of Investor Relations. Thanks so much for joining us here today.
Questions and Answers:
Eliana Rachel Merle - UBS Investment Bank, Research Division - AnalystI guess to kick it off, high level, you guys have accomplished a lot in the past year or so with mRNA vaccines for COVID-19. Maybe beyond COVID, where do you see mRNA going next?
Lavina Talukdar - Moderna, Inc. - Senior VP & Head of IR
So thanks so much for having me, Ellie, and that is such a great question because we are not just a COVID-19 vaccine company. We have 46 programs in various stages of clinical development.
But having said that, we have demonstrated the power of mRNA and
Trustpilot
